Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Respiratory Tract Diseases × Erlotinib Hydrochloride × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 2 Respiratory Tract Diseases 1 Neoplasms 1 MET Positive 1 Brain Neoplasms 1

Interventions

Gefitinib 1 Erlotinib Hydrochloride 1 AZD3759 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡